Monday, August 10, 2020 8:30:53 AM
BY GlobeNewswire
— 7:15 AM ET 08/10/2020
https://ir.ibioinc.com/press-releases/detail/130/ibio-announces-second-covid-19-vaccine-program
NEW YORK, Aug. 10, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (IBIO) (“iBio” or the “Company”), a biotechnology corporation and biologics contract manufacturing organization, today provided an update on one of its proprietary vaccine candidates being designed to prevent infection from the SARS-CoV-2 virus. iBio is investigating an array of adjuvants in combination with iBio’s proprietary lichenase carrier molecule (“LicKMTM”) fused to a coronavirus subunit protein (“IBIO-201”) with the goal of producing a safe and effective vaccine for COVID-19 disease, and especially one for our most vulnerable populations, including the elderly.
Ten distinct preclinical study arms for the IBIO (IBIO)-201 antigen-adjuvant combinations have been concluded. These include combinations delivered via intramuscular and intranasal routes, and datasets are under evaluation.
Anti-SARS-CoV-2 spike titers to IBIO IBIO)-201were observed 21 days after immunization. Titers continued to increase over the 42-day study. Distinct, favorable Th1 and Th2 immune profiles were observed.
Early functional testing of mouse antisera from IBIO (IBIO)-201 immunized mice demonstrates the presence of antibodies that interfere with the binding of SARS-CoV-2 spike protein sequences to human ACE2 in ex vivo assays. iBio plans to conduct additional testing of IBIO (IBIO)-201 antisera, including further evaluations of neutralizing titers in multiple assay formats. In addition, significant immune profiling studies are ongoing to evaluate safety and immune protection correlates, including antigen-specific T cell responses and memory B cell testing. The additional testing for both IBIO (IBIO)-201 and IBIO (IBIO)-200 is occurring in collaboration with the Texas A&M University System (“TAMUS”) laboratories.
“We are encouraged by these pre-clinical data, which demonstrate IBIO (IBIO)-201’s ability to generate an immune response to SARS-CoV-2 sequences and neutralize protein interaction,” said Tom Isett, Chairman & CEO of iBio. “We expect to gain more insight as we complete data analysis of both of our COVID-19 vaccine candidates.”
About iBio’s COVID-19 Vaccine Development Programs
On March 11, 2020, the Company filed four provisional patent applications with the U.S. Patent and Trademark Office in support of its COVID-19 vaccine platforms. The virus-like particle (“VLP”) program (“IBIO-200”) was subsequently announced on March 18, 2020. The LicKM-Subunit program (“IBIO-201”) was announced on June 3, 2020. If the program(s) move into clinical trials, iBio has the capability to rapidly develop and manufacture at clinical and commercial scales in its 130,000 square foot facility in Bryan, Texas. Originally built in 2010 with funding from the U.S. Defense Advanced Research Projects Agency [DARPA], iBio’s FastPharming Facility® was part of the “Blue Angel” initiative to establish factories capable of rapid delivery of medical countermeasures in response to a disease pandemic.
About iBio, Inc. (IBIOiBio is a global leader in plant-based biologics manufacturing. Its FastPharming System® combines vertical farming, automated hydroponics, and glycan engineering technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, bioinks and other proteins. The Company’s subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services. iBio’s FastGlycaneering Development Service™ includes an array of new glycosylation technologies for engineering high-performance recombinant proteins. Additionally, iBio is developing proprietary products, which include IBIO (IBIO)-100 for the treatment of fibrotic diseases, and vaccines for COVID-19 disease. For more information, visit www.ibioinc.com
Recent IBIO News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/20/2024 08:14:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2024 08:07:16 PM
- iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 09/20/2024 08:05:00 PM
- iBio to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 09/03/2024 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 09:24:33 PM
- iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development • GlobeNewswire Inc. • 08/12/2024 08:30:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/06/2024 09:02:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/26/2024 01:03:41 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 07/25/2024 09:05:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/09/2024 08:02:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:10:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 08:08:04 PM
- iBio Closes Sale of Manufacturing Facility in Texas • GlobeNewswire Inc. • 06/03/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 10:55:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2024 08:32:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2024 08:30:55 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 08:14:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 08:08:29 PM
- iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/13/2024 08:05:00 PM
- iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases • GlobeNewswire Inc. • 03/27/2024 11:00:00 AM
- iBio Announces $15.0 Million Private Placement • GlobeNewswire Inc. • 03/26/2024 11:35:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:59:30 PM
- iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka • GlobeNewswire Inc. • 02/26/2024 12:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 09:55:17 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM